13/02/2026
This week Duchenne Australia have been at TREAT-NMD in Lisbon, Portugal, contributing to global discussions, shaping the future of Duchenne care and research.
As a parent-led organisation, our advocacy is grounded in lived experience and sector leadership - informing conversations on clinical trial design, standards of care, earlier diagnosis and equitable access to emerging therapies.
In a rapidly evolving global landscape, challenges remain. What’s clear is that collaboration across researchers, industry and patient organisations is essential to accelerating progress.
We’re engaging directly with international leaders to ensure Australian families are represented in global decision-making.
Duchenne Australia remains committed to active, constructive collaboration to move outcomes for the Australian community.